Biodexa Sets 1-for-8 Reverse ADS Split for October 26
Summary
Biodexa is implementing a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares. The move aims to boost the ADS price above NASDAQ's minimum bid threshold.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
The ADS ratio changes from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. Every 8 old ADSs will be exchanged for 1 new ADS.
-
NASDAQ Compliance Pressure
The ratio change is designed to raise the ADS price above NASDAQ's $1.00 minimum bid requirement. The last reported closing price on October 12, 2026 was $0.3832.
-
Going Concern Backdrop
The reverse split follows a going concern warning disclosed in 1H26 results, with cash of only £3.23 million as of June 30, 2026, down from £8.53 million at year-end.
-
Prior Reverse Split Approved
Shareholders approved a 1-for-10,000 reverse stock split on July 29, 2026. This ADS ratio change is a separate mechanism to achieve NASDAQ compliance.
Analysis · BDRX · Life Sciences
Effective on or about October 26, 2026, Biodexa will adjust its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares. For ADS holders, this is equivalent to a one-for-eight reverse split—every 8 old ADSs will be exchanged for 1 new ADS. The ordinary shares themselves remain unaffected. This move follows the shareholder-approved 1-for-10,000 reverse stock split from July 29, 2026, and comes amid a going concern warning and a cash balance of only £3.23 million as of June 30, 2026. The ratio change is designed to lift the ADS price above NASDAQ's minimum bid requirement, but it does not alter the company's underlying market capitalization or financial condition.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.